|  |  |
| --- | --- |
| **Report title** | Monthly Finance Performance Report Month 11 – February 2021 |
| **Report from**  | Jonathan Wilson, Chief Financial Officer |
| **Prepared by** | Justin Betts, Deputy Chief Financial Officer  |
| **Link to strategic objectives** | Deliver financial sustainability as a Trust |

|  |
| --- |
| **Executive summary****Income and Expenditure** For March the Trust is reporting:- * a £17.8m deficit year to date pre COVID support and top-up funding;
* £37.6m of COVD support and top-up funding, resulting in a
* £19.8m surplus year to date.

Clinical activity levels recorded in March compared to 2019/20 were 69% of A&E activity, 88% Elective, 81% Core Outpatients (excluding DGH or 91% inclusive), and 105% injections activity. Excess funding over activity levels contributed £0.1m in month and £16.7m year to date to the Trusts surplus reported position.**Capital Expenditure*** Capital expenditure to 31st March totalled £14.8m, against a plan of £18.1m predominantly linked to network strategy decision timelines surrounding consolidation which meant schemes were not be able to be executed in this financial year and have been incorporate into 2022/23 TIF funding schemes, and slippage within schemes such as London Claremont Centre.
 |
| **Quality implications**Patient safety has been considered in the allocation of budgets. |
| **Financial implications**Delivery of the financial control total will result in the Trust being eligible for additional benefits that will support its future development. |
| **Risk implications**Potential risks have been considered within the reported financial position and the financial risk register is discussed at the Audit Committee. |
| **Action Required/Recommendation**The board is asked to consider and discus the attached report. |
| **For Assurance** |  | **For decision** |  | **For discussion** | **✓** | **To note** | **✓** |